need volume of 2mil +++.hopefully 5mil+.look at the options for 2012.market seems to think $3 is obtainable.no shorties,the fact there is really no short interest,probably wont get a huge pop if approved.JMHO
You sure talk a lot without saying anything relevant. So respond to this Einstein: The real discrepancy is the lack of validation for the 5mg dose. The 10mg dose was filed with the FDA, but since Alexza was required to change to a 5mg dose, and a new validation has to be completed. I don't think Alexza has completed the validation, because they were having trouble with the 5mg dosage as of a couple of months ago. Plus, they laid off a great majority of engineers and validation people to complete the new requirements.
On a lighter note, they run out of money in July.